We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure

By MedImaging International staff writers
Posted on 02 May 2024

Imaging inflammation using traditional radiological techniques presents significant challenges, including radiation exposure, poor image quality, high costs, and invasive procedures. Now, new contrast agents and imaging technology are being developed to improve the monitoring of inflammatory disorders like inflammatory bowel disease, arthritis, hepatitis, and other autoimmune diseases.

A team of researchers at the University of Missouri (Columbia, MO, USA) is developing new methods to track the progression of inflammatory disorders using cutting-edge imaging technologies. They are developing the first probiotic bacterial-based contrast agent suitable for use with multispectral optoacoustic tomography (MSOT). This novel contrast agent incorporates lactic acid bacteria that produce a distinctive glowing blue color in MSOT imaging. MSOT itself is a non-radiative imaging technology that offers high-resolution images of biological tissues using light and sound, similar to an ultrasound procedure. This advancement marks a significant leap in creating bacterial-based, optoacoustic detectable contrast agents for the diagnosis and management of inflammation.


Image: The multi-spectral optoacoustic tomography (MSOT) machine generates images of biological tissues (Photo courtesy of University of Missouri)
Image: The multi-spectral optoacoustic tomography (MSOT) machine generates images of biological tissues (Photo courtesy of University of Missouri)

“Because this non-invasive technique does not require exposure to radiation it is possible to more regularly obtain imaging from patients to monitor disease progression and response to therapy,” said Jorge Gomez-Gutierrez, PhD, an associate professor of pediatrics at the University of Missouri School of Medicine who is leading the research team. “Unlike the synthetic contrast agents currently available, the natural agent we are developing is less expensive to produce and doesn’t offer the downsides of the synthetic agents, which can aggravate a patient’s IBD or colitis.”

Related Links:
University of Missouri


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ceiling-Mounted Digital Radiography System
Radiography 5000 C
Ultrasound System
Acclarix AX9
Wireless Handheld Ultrasound System
TE Air

Latest Nuclear Medicine News

New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy

New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients

New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access